info@biomedres.us   +1 (720) 414-3554   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Mini ReviewOpen Access

BCL-2 Inhibition in the Treatment of Multiple Myeloma

Volume 4 - Issue 4

Gabor Mikala*

  • Author Information Open or Close
    • Department of Haematology and Stem Cell Transplantation South-Pest Central Hospital, National Institute for Haematoloy and Infectious Diseases, Hungary

    *Corresponding author: Gabor Mikala, Department of Haematology and Stem Cell Transplantation South-Pest Central Hospital, National Institute for Haematology and Infectious Diseases, Budapest, Hungary, H-1097

Received: May 11, 2018;   Published: May 18,2018

DOI: 10.26717/BJSTR.2018.04.001087

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Multiple myeloma is the second most common haematological malignancy – though multiple effective therapeutic options exist for disease control – cure of myeloma still remains the exception. Our present therapeutic approach is founded on apoptosis induction in tumor cells by various different stimuli, most commonly by DNA damage, oxidative or endoplasmic reticular (proteomic) stress. Effective treatment of relapsed and/or refractory disease rarely provides long term disease control mainly due to development of resistance to pharmacological induction of apoptosis pathways.

Abstract| Introduction| References|